NanoViricides Inc. (NNVC)

[BonelessCat]

NanoViricides Inc. to Present at the 13th Annual Rodman & Renshaw Healthcare Conference
Today : Tuesday 13 September 2011

NanoViricides, Inc. (OTC BB: NNVC) (the "Company") announced that its CEO, Dr. Eugene Seymour, will present at the Rodman & Renshaw Annual Global Investment Conference being held in New York City. He will discuss the nanoviricides® platform technology, the Company’s drug pipeline, its recent successes with animal studies for the Company’s influenza therapeutic FluCide™, and progress towards the initial FDA submission.

The NanoViricides investor presentation is scheduled for Tuesday, September 13, 2011, at 3:15 pm Eastern Time. The presentation will be webcast live and then archived for 90 days at http://www.wsw.com/webcast/rrshq20/nnvc.

The Company has recently announced that it has chosen a clinical candidate, NV-INF-1, in its anti-influenza drug program (FluCide™) to develop for FDA submission. The Company believes that a single course therapy easily administered by a medical office is feasible for out-patients.

The Company has also recently announced significant successes in its anti-HIV drug program, viz. HIVCide™. The best HIVCide candidate in a recent SCID-hu Thy/Liv mouse model study showed effectiveness against HIV-1 similar to a three drug HAART (highly active anti-retroviral therapy) cocktail even when HIVCide was administered at a much lower total dosage. What is more significant, this nanoviricide drug candidate continued to work to suppress HIV viral load for at least 28 days beyond last drug administration. These data along with previous similar successes in anti-HIV drug development indicate that HIVCide may provide a “functional cure” of HIV/AIDS either alone or in combination with other drugs.

Further information on the Rodman & Renshaw Annual Global Investment Conference can be found at www.rodm.com/conferences.
http://ih.advfn.com/p.php?pid=nmona&article=49152699&symbol=NNVC